Blog

CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ — Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drugs that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced that management will be participating in the 5^th Annual Needham Private Biotech and MedTech Company Virtual 1×1 Forum taking place October 14-15, 2025.

Apnimed will be hosting investor meetings virtually on Tuesday, October 14, and Wednesday, October 15.

About Apnimed
Apnimed is a privately held, clinical-stage pharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the treatment landscape for sleep-related breathing diseases. We believe the introduction of simple, once-nightly oral drugs may dramatically expand diagnosis and the reach of treatment for people with OSA. OSA, like other common chronic diseases such as diabetes or hypertension, would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive.

Apnimed is advancing a robust pipeline of oral pharmaceutical product candidates designed to improve oxygenation in individuals living with OSA and other chronic sleep-related breathing diseases. Our lead candidate, AD109, could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. Apnimed is also developing several therapies as part of its joint venture with Shionogi & Co., Ltd., Shionogi-Apnimed Sleep Science.

Learn more at apnimed.com or follow us on X and LinkedIn.

Media Contact:
[email protected]

Investor Contact:
[email protected]

SOURCE Apnimed, Inc.

AMSTERDAM – Stellantis N.V. announced today that its Third Quarter 2025 Shipments and Revenues will be released on Thursday, October 30, 2025.

A live webcast and conference call for the Third Quarter Shipments and Revenues will begin at 1:00 p.m. CET / 8:00 a.m. EDT on Thursday, October 30, 2025.

The related press release and presentation materials are expected to be posted under the Investors section of the Stellantis corporate website at approximately 8 a.m. CET / 3 a.m. EDT on Thursday, October 30, 2025.

Details for accessing this presentation are available under the Investors section of the Stellantis corporate website. For those unable to participate in the live session, a recorded replay will be accessible following the event.

About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep_®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit www.stellantis.com.

(more…)